EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents

Wojciech Luboń iD, Małgorzata Luboń iD, Anna Agaś-Lange iD, Mariola Dorecka iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311744 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wojciech Luboń und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medical Sciences, Medical University of Silesia, 40-514 Katowice, Poland. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Eye Diseases, Immunomodulating Agents. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which ocular involvement represents a clinically significant yet frequently underrecognized contributor to morbidity. Ocular manifestations in SLE may arise from disease activity itself, but also as adverse effects of long-term pharmacological therapy. With the advent of targeted immunomodulatory agents, the therapeutic landscape of SLE has expanded beyond conventional drugs such as hydroxychloroquine and corticosteroids toward biologics and small molecules designed to interfere with specific immunological pathways. These advances have improved systemic disease control and survival; however, their ophthalmological safety profiles remain only partially defined. This review synthesizes current evidence on ocular adverse events associated with both traditional and emerging SLE therapies. Established agents, particularly hydroxychloroquine and corticosteroids, are consistently linked to complications including retinopathy, posterior subcapsular cataracts, steroid-induced glaucoma, and central serous chorioretinopathy. In contrast, recently approved or investigational therapies—such as belimumab, anifrolumab, voclosporin, dual BAFF/APRIL inhibitors, rituximab, JAK inhibitors, CD40/CD40L blockade, CD38 inhibition, and mesenchymal stromal cell-based strategies—have limited but evolving safety data, with potential ocular adverse events spanning inflammatory, vascular, neuro-ophthalmic, and structural domains. Although ocular complications appear infrequent in clinical trials, underdetection in real-world practice and insufficient long-term monitoring may underestimate their true incidence. These findings highlight the need for systematic ophthalmological surveillance in patients receiving immunomodulatory therapies for SLE. Early recognition and timely management of ocular toxicity are crucial to safeguarding visual function and optimizing long-term therapeutic outcomes in this vulnerable patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicEye DiseasesImmunomodulating AgentsHumansHydroxychloroquineAdrenal Cortex Hormones

Stichwörter der Autor:innen

biologic agentsimmunomodulationocular adverse eventsophthalmological safetysystemic lupus erythematosustargeted therapies

Substanzen

HydroxychloroquineAdrenal Cortex HormonesImmunomodulating Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medical Sciences, Medical University of Silesia, 40-514 Katowice, Poland.
  • Department of Ophthalmology, Professor K. Gibiński University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland.

ORCID-Profile: Wojciech Luboń, Małgorzata Luboń, Anna Agaś-Lange, Mariola Dorecka

Zitieren

APA

Luboń, W., Luboń, M., Agaś-Lange, A., & Dorecka, M. (2025). Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311744

Vancouver

Luboń W, Luboń M, Agaś-Lange A, Dorecka M. Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311744

BibTeX
@article{Lubo2025,
  author = {Luboń, Wojciech and Luboń, Małgorzata and Agaś-Lange, Anna and Dorecka, Mariola},
  title = {Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311744}
}
Kostenlos starten →